Stay updated with breaking news from Nasdaq Bcab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BioAtla (NASDAQ:BCAB – Get Rating) had its price objective cut by HC Wainwright from $20.00 to $17.00 in a report issued on Friday, The Fly reports. They currently have a buy rating on the stock. Separately, EF Hutton Acquisition Co. I initiated coverage on shares of BioAtla in a report on Thursday, January 5th. They […]
- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS)...
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...
BioAtla, Inc. (NASDAQ:BCAB – Get Rating) insider Christian Vasquez acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, June 9th. The stock was bought at an average price of $2.97 per share, with a total value of $29,700.00. Following the completion of the acquisition, the insider now directly owns 74,525 shares of […]